Abbisko Therapeutics Receives IND Clearance for Innovative Achondroplasia Treatment

Abbisko Cayman Limited ( (HK:2256) ) has shared an announcement.

Abbisko Therapeutics announced that the Center for Drug Evaluation of the China National Medical Products Administration has cleared the IND application for ABSK061, a highly selective FGFR2/3 inhibitor, for treating children with achondroplasia. This development marks a significant step for Abbisko as ABSK061 is the first FGFR2/3 inhibitor to enter clinical trials globally, aiming to provide a wider therapeutic window and improved clinical efficacy compared to first-generation inhibitors, potentially impacting the treatment landscape for achondroplasia, a rare disorder with no specific treatments in China.

More about Abbisko Cayman Limited

Abbisko Therapeutics Co., Ltd., founded in April 2016 and based in Shanghai, is an oncology-focused biopharmaceutical company dedicated to discovering and developing innovative medicines for unmet medical needs in China and globally. The company was established by experienced professionals from top multinational pharmaceutical companies and has built an extensive pipeline of programs focused on precision oncology and immuno-oncology.

YTD Price Performance: 84.57%

Average Trading Volume: 4,220,303

Technical Sentiment Signal: Sell

Current Market Cap: HK$5.38B

See more data about 2256 stock on TipRanks’ Stock Analysis page.